129 related articles for article (PubMed ID: 16223821)
21. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
22. Need for differential discounting of costs and health effects in cost effectiveness analyses.
Brouwer WB; Niessen LW; Postma MJ; Rutten FF
BMJ; 2005 Aug; 331(7514):446-8. PubMed ID: 16110075
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
24. Economic analysis of complementary medicine: a systematic review.
White AR; Ernst E
Complement Ther Med; 2000 Jun; 8(2):111-8. PubMed ID: 10859604
[TBL] [Abstract][Full Text] [Related]
25. Should NICE's threshold range for cost per QALY be raised? No.
Raftery J
BMJ; 2009 Jan; 338():b185. PubMed ID: 19171562
[No Abstract] [Full Text] [Related]
26. How should we value future health? Was NICE right to change?
Raftery J
Value Health; 2013; 16(5):699-700. PubMed ID: 23947961
[No Abstract] [Full Text] [Related]
27. Should NICE's threshold range for cost per QALY be raised? Yes.
Towse A
BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561
[No Abstract] [Full Text] [Related]
28. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
[TBL] [Abstract][Full Text] [Related]
29. Office of Alternative Medicine supports research to evaluate effectiveness, safety, and cost of alternative and complementary treatments.
Mast E
ONS News; 1998 Jun; 13(6):9. PubMed ID: 10569042
[No Abstract] [Full Text] [Related]
30. Cost-effectiveness studies.
Br Med J; 1978 Sep; 2(6141):848-9. PubMed ID: 101265
[No Abstract] [Full Text] [Related]
31. How NICE may be outflanked.
Ferner RE; McDowell SE
BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
[No Abstract] [Full Text] [Related]
32. Alternatives. Do complementary therapies have a place in the modern-day NHS?
Holyoake D
Nurs Stand; 1998 Mar 18-24; 12(26):23. PubMed ID: 9697509
[No Abstract] [Full Text] [Related]
33. Drugs for cancer and copayments.
Finlay I; Crisp N
BMJ; 2008 Jun; 337(7660):a527. PubMed ID: 18595953
[TBL] [Abstract][Full Text] [Related]
34. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
35. Cheap research is likely to be biased.
White A; Hart A
Complement Ther Med; 2002 Jun; 10(2):59-60. PubMed ID: 12481952
[No Abstract] [Full Text] [Related]
36. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk.
Fairbairn TA; Meads DM; Hulme C; Mather AN; Plein S; Blackman DJ; Greenwood JP
Heart; 2013 Jul; 99(13):914-20. PubMed ID: 23696198
[TBL] [Abstract][Full Text] [Related]
37. The New and Non-Transparent Cancer Drugs Fund.
Wood EM; Hughes DA
Pharmacoeconomics; 2020 Jan; 38(1):1-4. PubMed ID: 31828737
[No Abstract] [Full Text] [Related]
38. The practice of complementary medicine outside the National Health Service.
Dolan G; Lewith GT
J Altern Complement Med; 1999 Jun; 5(3):297-300. PubMed ID: 10381254
[No Abstract] [Full Text] [Related]
39. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
40. Personal health budgets: a new way of accessing complementary therapies?
Rogers J
Complement Ther Clin Pract; 2011 May; 17(2):76-80. PubMed ID: 21457895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
